DCN Dx has received a growth equity investment from Martis Capital
DCN Dx, a leading provider of contract development services, has received a growth equity investment from Martis Capital.
DCN Dx offers contract development services for clients seeking to explore, develop and commercialize rapid diagnostic tests related to lateral flow assay. DCN Dx supports an array of customers including global diagnostics manufacturers, nonprofits seeking tests for low-resource settings and start-ups launching diagnostic-based products. Over the past 15 years, DCN Dx has successfully developed more than 100 rapid diagnostic tests for its customers.
Martis Capital is a private equity firm which manages more than US$1.2 billion of equity and is focused exclusively on investing in middle-market growth companies in the healthcare industry.
One of Oaklins’ teams in the USA, together with Pegasus Capital, served as a financial advisor to DCN Dx, in connection with a growth equity investment from Martis Capital.


Talk to the deal team

Bradford A. Adams
Managing Director
Boston, United StatesOaklins TM Capital

Michael S. Goldman
Managing Director
New York, United StatesOaklins TM Capital

James McLaren
Managing Director
New York, United StatesOaklins TM Capital
Related deals
Coastal Insurance Underwriters has been acquired by Constellation Affiliated Partners
The shareholders of Coastal Insurance Underwriters have sold the firm to Constellation Affiliated Partners.
Learn moreBlue Equity is partnering with Bang & Beenfeldt
The private shareholders of Bang & Beenfeldt A/S have sold the company to Blue Equity, with a subsequent reinvestment in the new company.
Learn moreGroupe Voie Lactée has been acquired by Initiative & Finance
JFC Industrie has sold Groupe Voie Lactée to Initiative & Finance.
Learn more